NCT06654336View on ClinicalTrials.gov

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2031

Study Completion Date

June 30, 2031

Conditions
Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Interventions
RADIATION

Recurrence-directed therapy (RDT)

RDT options include radiotherapy or surgical resection.

DRUG

ELIGARD 22.5mg

ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.

Trial Locations (1)

Unknown

Juravinski Cancer Centre, Hamilton

All Listed Sponsors
collaborator

Ontario Clinical Oncology Group (OCOG) - McMaster University

UNKNOWN

collaborator

TOLMAR PHARMACEUTIQUES CANADA, INC.

UNKNOWN

lead

Ontario Clinical Oncology Group (OCOG)

OTHER